Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock Position Lifted by Barclays PLC

Barclays PLC grew its position in Fennec Pharmaceuticals Inc (NASDAQ:FENC) by 274.3% in the third quarter, Holdings Channel.com reports. The fund owned 31,319 shares of the company’s stock after buying an additional 22,951 shares during the period. Barclays PLC’s holdings in Fennec Pharmaceuticals were worth $157,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp boosted its holdings in Fennec Pharmaceuticals by 2.2% in the third quarter. State Street Corp now owns 328,259 shares of the company’s stock worth $1,641,000 after purchasing an additional 7,053 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Fennec Pharmaceuticals by 42.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock worth $420,000 after buying an additional 20,602 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of Fennec Pharmaceuticals in the 2nd quarter worth about $409,000. Advantage Alpha Capital Partners LP acquired a new position in shares of Fennec Pharmaceuticals in the 3rd quarter valued at about $264,000. Finally, Rhumbline Advisers grew its position in shares of Fennec Pharmaceuticals by 44.7% during the 2nd quarter. Rhumbline Advisers now owns 29,110 shares of the company’s stock valued at $178,000 after buying an additional 8,987 shares during the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

FENC has been the topic of a number of recent research reports. Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a report on Tuesday, December 17th. Finally, Wedbush restated an “outperform” rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research note on Friday, December 20th.

Fennec Pharmaceuticals Trading Up 0.3 %

Fennec Pharmaceuticals stock opened at $6.10 on Wednesday. Fennec Pharmaceuticals Inc has a 52-week low of $3.96 and a 52-week high of $11.49. The company has a quick ratio of 7.64, a current ratio of 7.80 and a debt-to-equity ratio of 9.86. The firm has a market capitalization of $167.57 million, a price-to-earnings ratio of -60.99 and a beta of 0.34. The firm has a 50-day moving average price of $5.51 and a two-hundred day moving average price of $5.52.

Insider Activity

In other Fennec Pharmaceuticals news, Director Chris A. Rallis sold 6,409 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.14, for a total transaction of $39,351.26. Following the completion of the transaction, the director now owns 52,214 shares in the company, valued at approximately $320,593.96. The trade was a 10.93 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $6.08, for a total value of $60,800.00. Following the transaction, the director now directly owns 83,863 shares in the company, valued at $509,887.04. This trade represents a 10.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,636 shares of company stock valued at $115,437. Insiders own 10.98% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.